During the past decade, Yamanashi Prefectural Central Hospital conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 16 clinical trials were completed, i.e. on average, 42.1% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 12 clinical trials were completed. i.e. 52.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yamanashi Prefectural Central Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 10 trials, followed by "Pfizer" with 7 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Galapagos NV" with 3 trials sponsored and "Gilead Sciences" with 3 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yamanashi Prefectural Central Hospital" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator and "Japan Blood Products Organization" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Yamanashi Prefectural Central Hospital" are "Ulcerative Colitis" (6 trials), "Crohn's Disease" (3 trials), "Psoriasis" (3 trials), "Atopic Dermatitis" (2 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "Yamanashi Prefectural Central Hospital" in a lesser frequency.

Most popular intervention types in "Yamanashi Prefectural Central Hospital" are "Drug" (40 trials), "Other" (3 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Filgotinib" (4 trials), "Guselkumab" (3 trials), "Baricitinib" (2 trials) and "Dexamethasone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Yamanashi Prefectural Central Hospital" are 42 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Yamanashi Prefectural Central Hospital". undefined are not yet recruiting, 14 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in Yamanashi Prefectural Central Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Yamanashi Prefectural Central Hospital, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".